Treatment selection for stage IIIA Hodgkin's disease patients

Journal Article · Thu Aug 01 04:00:00 EDT 1985 · Int. J. Radiat. Oncol., Biol. Phys.; (United States)

DOI:https://doi.org/10.1016/0360-3016(85)90329-3· OSTI ID:5323095

Prosnitz, L R; Cooper, D; Cox, E B; Kapp, D S; Farber, L R

Two treatment policies for the therapy of patients with Stage IIIA Hodgkin's disease are compared. From 1969-1976, 49 newly diagnosed and pathologically staged IIIA patients received total nodal irradiation (TNI) alone (no liver irradiation). Although actuarial survival was 80% at 5 years and 68% at 10 years, actuarial freedom from relapse was only 38% at 5 years. Accordingly, a new treatment policy was instituted in 1976. Patients with either CS IIIA disease, multiple splenic nodules, IIIA with a large mediastinal mass or III/sub 2/, received combined modality therapy (combination chemotherapy and irradiation). All others received TNI. Thirty-six patients have been treated under the new program. The actuarial survival is 90% at 5 years and the relapse-free survival is 87%, suggesting the superiority of this approach. Complications from the treatments are discussed.

• Research Organization: Duke Univ. Medical Center, Durham, NC
• OSTI ID: 5323095
• Journal Information: Int. J. Radiat. Oncol., Biol. Phys.; (United States), Journal Name: Int. J. Radiat. Oncol., Biol. Phys.; (United States) Vol. 11:8; ISSN IOBPD
• Country of Publication: United States
• Language: English

Related Subjects

550600 -- Medicine
550603* -- Medicine-- External Radiation in Therapy-- (1980-)
560151 -- Radiation Effects on Animals-- Man
62 RADIOLOGY AND NUCLEAR MEDICINE
63 RADIATION, THERMAL, AND OTHER ENVIRON. POLLUTANT EFFECTS ON LIVING ORGS. AND BIOL. MAT.
CHEMOTHERAPY
DISEASES
EXTERNAL IRRADIATION
HEMIC DISEASES
HODGKINS DISEASE
IRRADIATION
LEUKEMIA
LYMPH NODES
LYMPHATIC SYSTEM
LYMPHOMAS
MEDICINE
NEOPLASMS
NUCLEAR MEDICINE
PARTIAL BODY IRRADIATION
PATIENTS
PNEUMONITIS
RADIOINDUCTION
RADIOLOGY
RADIOTHERAPY
SIDE EFFECTS
THERAPY